Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

SMMT

NEW YORK, NY / ACCESSWIRE / March 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Summit Therapeutics Inc. ("Summit" or "the Company") (NASDAQ:SMMT). Investors who purchased Summit securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SMMT.

Investigation Details:

On February 20, 2024, Summit reported its financial results for the fourth quarter and full year 2023 and "provide[d] an update on its operational progress." Among other items, Summit reported non-GAAP earnings per share of -$0.04 and no revenue. Summit also disclosed that the maturity date for a $100 million note from its chairman and Chief Executive Officer had been extended from September 6, 2024 to April 1, 2025 and filed a mixed shelf registration statement for the potential sale of up to $450 million of its securities. On this news, Summit's stock price fell $1.33 per share, or 26.23%, to close at $3.74 per share on February 20, 2024.

What's Next?

If you are aware of any facts relating to this investigation or purchased Summit securities, you can assist this investigation by visiting the firm's site: bgandg.com/SMMT. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View the original press release on accesswire.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today